Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity

We seek to further addresss the questions posed by Moseson et al. regarding whether any residual crystal level, size, or characteristic is acceptable in an amorphous solid dispersion (ASD) such that its stability, enhanced dissolution, and increased bioavailability are not compromised. To address th...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Daniel A., Miller, Dave A., Santitewagun, Supawan, Zeitler, J. Axel, Su, Yongchao, Williams, Robert O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683684/
https://www.ncbi.nlm.nih.gov/pubmed/34977559
http://dx.doi.org/10.1016/j.ijpx.2021.100092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683684/
https://www.ncbi.nlm.nih.gov/pubmed/34977559
http://dx.doi.org/10.1016/j.ijpx.2021.100092

Ejemplares similares